Member of the Association of American Physicians
His primary areas of investigation include Immunology, Immune system, Immunity, Cancer and Antigen. His Immunology research incorporates themes from Cytotoxic T cell and Breast cancer. His biological study deals with issues like Cancer research, which deal with fields such as Merkel cell polyomavirus.
His study looks at the relationship between Immune system and fields such as Adjuvant, as well as how they intersect with chemical problems. His Immunity study combines topics from a wide range of disciplines, such as Vaccination, Tetanus, Virology, T cell and Humoral immunity. His work investigates the relationship between IL-2 receptor and topics such as Pathogenesis that intersect with problems in FOXP3.
Mary L. Disis mostly deals with Immunology, Immune system, Cancer, Antigen and Breast cancer. His study involves Immunity, T cell, Antibody, Vaccination and Immunotherapy, a branch of Immunology. His research is interdisciplinary, bridging the disciplines of Adjuvant and Immune system.
His Cancer research is multidisciplinary, incorporating elements of Cancer research, Disease, Immunization and Bioinformatics. His research investigates the connection with Antigen and areas like Cytotoxic T cell which intersect with concerns in CD8. His Breast cancer research includes themes of Autoantibody, Genetically modified mouse and Oncology.
His primary scientific interests are in Cancer, Internal medicine, Breast cancer, Immune system and Cancer research. The various areas that Mary L. Disis examines in his Cancer study include Acquired immune system, Carcinoma and MEDLINE. Within one scientific family, Mary L. Disis focuses on topics pertaining to Oncology under Internal medicine, and may sometimes address concerns connected to Tumor-infiltrating lymphocytes, Chemotherapy and Metastatic breast cancer.
When carried out as part of a general Breast cancer research project, his work on Mammary tumor is frequently linked to work in In patient, therefore connecting diverse disciplines of study. His study on Immune system is covered under Immunology. His work deals with themes such as Adjuvant, Stem cell, Triple-negative breast cancer, Cytotoxic T cell and Genetically modified mouse, which intersect with Cancer research.
His scientific interests lie mostly in Cancer, Immune system, Immunotherapy, Internal medicine and Immunology. His biological study spans a wide range of topics, including Acquired immune system and Public relations. Mary L. Disis interconnects Cognitive science and Biomarker in the investigation of issues within Immune system.
Mary L. Disis focuses mostly in the field of Immunotherapy, narrowing it down to topics relating to Tumor microenvironment and, in certain cases, Tumor-infiltrating lymphocytes, Antigen processing, Immunity and Cancer immunotherapy. The Internal medicine study combines topics in areas such as Gastroenterology and Oncology. In general Immunology, his work in Antigen and ELISPOT is often linked to Outcome linking many areas of study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel;George Coukos;Linhua Zou;Xavier Alvarez.
Nature Medicine (2004)
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
K. L. Knutson;M. L. Disis.
Cancer Immunology, Immunotherapy (2005)
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Mary L. Disis;Emanuel Calenoff;Graham McLaughlin;Ann E. Murphy.
Cancer Research (1994)
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
Keith L. Knutson;Kathy Schiffman;Mary L. Disis.
Journal of Clinical Investigation (2001)
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
Mary L. Disis;Theodore A. Gooley;Kristine Rinn;Donna Davis.
Journal of Clinical Oncology (2002)
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Mary L. Disis;Kenneth H. Grabstein;Paul R. Sleath;Martin A. Cheever.
Clinical Cancer Research (1999)
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines
Mary L. Disis;Helga Bernhard;Faith M. Shiota;Susan L. Hand.
Blood (1996)
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
Mary L. Disis;Serenella M. Pupa;Julie R. Gralow;Ruggero Dittadi.
Journal of Clinical Oncology (1997)
Immune Regulation of Cancer
Mary L. Disis.
Journal of Clinical Oncology (2010)
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.
Ulrich Keilholz;Jeffrey Weber;James H. Finke;Dmitry I. Gabrilovich.
Journal of Immunotherapy (2002)
JAMA oncology
(Impact Factor: 33.006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Mayo Clinic
University of Washington
Stanford University
University of California, San Francisco
Northwestern University
University of Washington
Vanderbilt University Medical Center
Johns Hopkins University School of Medicine
Earle A. Chiles Research Institute
The University of Texas MD Anderson Cancer Center
Tel Aviv University
University of Virginia
University of Pennsylvania
Nagoya University
Missouri Botanical Garden
University of Washington
Agricultural University of Athens
University of Minho
Texas Tech University Health Sciences Center
Arizona State University
Centre national de la recherche scientifique, CNRS
United States Department of Veterans Affairs
University of Alberta
Geisinger Health System
University of Liège
University of Chieti-Pescara